Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

dy, the company's A-beta antibody holds the potential for slowing down the progression of Alzheimer's disease. Enrollment began in May 2009 in two multi-national Phase III registration studies - EXPEDITION and EXPEDITION 2. Each study will enroll 1,000 subjects for an 18-month treatment duration.
  • mGlu 2/3 Prodrug - An open-label study continues for this potential schizophrenia compound currently in Phase II of clinical development. The company plans to proceed with further efficacy testing, and anticipates initiating two large studies in the first half of 2010.
  • iGluR5 Receptor Antagonist - Work on this pain compound continues to progress. Phase II studies began in osteoarthritis and diabetic peripheral neuropathic pain in the second quarter of 2009. Other pain indications are also being considered, including migraine prevention.
  • Insomnia Compound LY2624803 - A Phase II study is ongoing and recently completed enrollment ahead of plan. Results are expected in the first half of 2010.
  • IL-17 antibody - This molecule continues to be studied for its potential in rheumatoid arthritis (RA) and in other autoimmune disorders. In August, a Phase IIb trial for IL-17 was initiated in RA designed to further elucidate the molecule's safety and efficacy and to establish a dosing regimen for Phase III trials. This trial is expected to conclude in early 2011.
  • BAFF antagonist - Enrollment was recently completed in two Phase II clinical trials for rheumatoid arthritis and, earlier this year, a Phase II study was initiated in patients with relapsing-remitting multiple sclerosis.
  • Oncology

    With the acquisition of ImClone and the progression of its own pipeline, Lilly is well along the way to building an oncology powerhouse. Within the oncology business unit, Lilly's three key cancer medicines - Alimta®, Gemzar® and Erbitux® - account for 14 percent of the
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
    4. Lilly Receives NCQA Design Certification for Depression Care Management Program
    5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
    6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
    7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
    8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
    9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
    10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
    11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
    (Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
    (Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
    Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
    ... Arrowhead Research,Corporation (NASDAQ: ARWR) announced the publication ... a study,demonstrating the anti-proliferative effect of the ... its lead anti-cancer,compound, CALAA-01., The paper, entitled ... Reduce Cell Proliferation In vitro and In,vivo", ...
    Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
    (Date:4/18/2014)... Ky. (April 21, 2014) -- A group of ... Medicine and the Sanders-Brown Center on Aging has ... depression and neuropsychological function in Parkinson,s disease (PD). ... Research , the study, which assessed cognitive function ... that the dopamine replacement therapy commonly used to ...
    (Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
    (Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
    (Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
    (Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
    Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
    ... , , SACRAMENTO, Calif., July 21 If ... should be aware of California,s laws on pet safety. The California Veterinary ... safe. , , "There are a lot ... of the CVMA. "By taking a few precautions, travel with your companion pets ...
    ... , ST. LOUIS, July 21 Young ... of Directors declared a quarterly dividend of $0.04 per share, payable September ... Board of Directors also authorized the repurchase of up to 500,000 shares ... 2010 replaces the current authorization which is scheduled to expire on July ...
    ... , OAKLAND, Calif., July 21 ... owned by Tenet Healthcare Corporation organized an unprecedented national protest ... , , Tenet healthcare workers ... Association (NNOC/CNA) and Service Employees International Union (SEIU) Healthcare leafleted ...
    ... HIV transmission to infants via pre-chewed food suggest ... also a need for more data , ... have uncovered the first cases in which HIV almost certainly was transmitted from ... in the pre-chewed food was most likely the infected blood in the saliva ...
    ... right, exercised lowered chances of cardiovascular trouble , TUESDAY, July ... the right foods, exercising and losing weight pay off in ... show. , The reports, both originating at Brigham and Women,s ... of the Journal of the American Medical Association , ...
    ... , LANSING, Mich., July 21 The ... rushed timeline to address health care reform and urged Michigan,s ... and priorities. , , ... to work with Congress and the President to reform the ...
    Cached Medicine News:Health News:Tips for Transporting Your Pet in California 2Health News:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2Health News:Tenet Nurses, Healthcare Workers Take Action to Protest Sick Leave Cuts 2Health News:Pre-chewed Food Could Transmit HIV 2Health News:Pre-chewed Food Could Transmit HIV 3Health News:Pre-chewed Food Could Transmit HIV 4Health News:Studies Affirm Value of Healthy Lifestyle 2Health News:Studies Affirm Value of Healthy Lifestyle 3Health News:Michigan Chamber of Commerce Raises Concerns With Flawed Federal Health Care Reform Proposal, Rushed Timeline 2
    Incontinence Pessaries...
    Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
    The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
    The Incontinence Dish is used to relieve stress incontinence and minor degrees of prolapse. The Incontinence Dish comes with and without support. It is available in eight different sizes....
    Medicine Products: